

## **Remedy Pharmaceuticals Finalizes Formulation of Lead Drug**

*Key development milestone reached in commercializing life-saving drug for acute central nervous system disorders.*

New York, NY, USA – July 18, 2008 – Remedy Pharmaceuticals, Inc. today announced that it had selected a formulation for its lead drug, RP-1127, for treatment of patients with stroke, traumatic brain injury and spinal cord injury.

“A number of potential formulations were under development over the past 18 months,” said Sven Jacobson, Chief Executive Officer of Remedy. “The final formulation, a proprietary intravenous solution, was selected after it proved to be highly stable and easy to administer.”

The Company now plans to conduct a Phase 1 trial to determine the pharmacologic actions of RP-1127 and its safety in humans.

“This drug could help save lives and improve quality of life for millions of people,” adds Jacobson. “We are now one step closer to achieving that objective.”

### **About RP-1127**

Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of  $NC_{Ca-ATP}$  channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

### **About Remedy Pharmaceuticals**

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: [info@remedypharmaceuticals.com](mailto:info@remedypharmaceuticals.com)